Teachers Retirement System of The State of Kentucky Acquires 13,900 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Teachers Retirement System of The State of Kentucky raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,020 shares of the company's stock after buying an additional 13,900 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.07% of Neurocrine Biosciences worth $7,745,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Hussman Strategic Advisors Inc. lifted its position in Neurocrine Biosciences by 200.0% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $2,787,000 after buying an additional 16,800 shares in the last quarter. Grandfield & Dodd LLC increased its stake in shares of Neurocrine Biosciences by 2.8% in the 1st quarter. Grandfield & Dodd LLC now owns 16,570 shares of the company's stock valued at $1,833,000 after acquiring an additional 459 shares during the last quarter. Segall Bryant & Hamill LLC increased its stake in Neurocrine Biosciences by 13.3% during the 1st quarter. Segall Bryant & Hamill LLC now owns 53,103 shares of the company's stock worth $5,873,000 after purchasing an additional 6,233 shares in the last quarter. Aurora Investment Counsel increased its stake in Neurocrine Biosciences by 1.3% during the 1st quarter. Aurora Investment Counsel now owns 10,520 shares of the company's stock worth $1,164,000 after purchasing an additional 138 shares in the last quarter. Finally, Xponance Inc. increased its stake in Neurocrine Biosciences by 0.8% during the 1st quarter. Xponance Inc. now owns 27,282 shares of the company's stock worth $3,017,000 after purchasing an additional 215 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Down 1.2%

Shares of NASDAQ NBIX traded down $1.65 during trading hours on Thursday, reaching $132.01. 412,771 shares of the stock traded hands, compared to its average volume of 1,287,605. The company has a market capitalization of $13.06 billion, a P/E ratio of 44.78, a price-to-earnings-growth ratio of 1.36 and a beta of 0.24. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $157.98. The company's 50-day simple moving average is $126.68 and its two-hundred day simple moving average is $121.38.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same period last year, the firm posted $1.20 earnings per share. Neurocrine Biosciences's quarterly revenue was up 11.1% on a year-over-year basis. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In related news, insider Jude Onyia sold 59,819 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the sale, the insider directly owned 18,289 shares in the company, valued at $2,385,982.94. The trade was a 76.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ingrid Delaet sold 457 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider owned 4,730 shares in the company, valued at $638,550. This represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 120,251 shares of company stock valued at $14,978,602. Company insiders own 4.80% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NBIX shares. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $145.00 price target on shares of Neurocrine Biosciences in a research note on Monday, June 2nd. The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a research note on Thursday, July 10th. They set a "buy" rating and a $182.00 price target for the company. Evercore ISI decreased their price target on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. UBS Group increased their price objective on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a report on Wednesday, July 9th. Finally, Truist Financial initiated coverage on Neurocrine Biosciences in a report on Monday. They issued a "buy" rating and a $163.00 price objective for the company. Three research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.87.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.